Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer

Eto, Kazunori; Kawakami, Hiroshi; Kuwatani, Masaki et al.

BRITISH JOURNAL OF CANCER, 2013, 108(7), 1488-1494

Permalink : https://hdl.handle.net/2115/53423

このアイテムのアクセス数:1,116件（2026-08-24 14:15 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
bjc.2013.108 pdf 1.01 MB 993

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/53423
タイトル
Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
著者
Eto, Kazunori ; Kawakami, Hiroshi ; Kuwatani, Masaki ; Kudo, Taiki ; Abe, Yoko ; Kawahata, Shuhei ; Takasawa, Akira ; Fukuoka, Midori ; Matsuno, Yoshihiro ; Asaka, Masahiro ; Sakamoto, Naoya
著者名
Eto, Kazunori
e-Rad_Researcher
80399823
著者名
Kawakami, Hiroshi
e-Rad_Researcher
50431375
著者名
Kuwatani, Masaki
著者名
Kudo, Taiki
著者名
Abe, Yoko
著者名
Kawahata, Shuhei
著者名
Takasawa, Akira
著者名
Fukuoka, Midori
著者名
Matsuno, Yoshihiro
e-Rad_Researcher
10113507
著者名
Asaka, Masahiro
e-Rad_Researcher
10334418
著者名
Sakamoto, Naoya
言語
英語
キーワード
EUS-FNA
hENT1
Notch3
unresectable pancreatic cancer
発行日
2013-04-16
出版者
NATURE PUBLISHING GROUP
収録物名
BRITISH JOURNAL OF CANCER
巻(号)
108(7)
ページ
1488-1494
抄録
Background: Pancreatic ductal carcinoma (PDC) is one of the most lethal human carcinomas. Expression patterns of some genes may predict gemcitabine (GEM) treatment efficacy. We examined predictive indicators of survival in GEM-treated patients by quantifying the expression of several genes in pre-treatment endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) samples from patients with PDC. Methods: The expressions of human equilibrative nucleoside transporter 1 (hENT1), deoxycitidine kinase, ribonucleoside reductase 1, ribonucleoside reductase 2 and Notch3 in EUS-FNA tissue samples from 71 patients with unresectable PDC were quantified using real-time reverse transcription-polymerase chain reactions and examined for correlations with GEM sensitivity. Results: The log-rank test detected no significant differences in overall survival between GEM-treated patients with low and high mRNA levels of all genes examined. However, low Notch3 mRNA expression was significantly associated with longer overall survival in a multivariate analysis for survival (P = 0.0094). High hENT1 expression level was significantly associated with a longer time to progression (P = 0.039). Interaction tests for GEM administration and hENT1 or Notch3 mRNA expression were statistically significant (P = 0.0054 and 0.0047, respectively). Conclusion: hENT1 and Notch3 mRNA expressions in EUS-FNA specimens were the key predictive biomarkers of GEM effect and GEM sensitivity in patients with unresectable PDC.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
PISSN
0007-0920
NCID
AA00574366
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1038/bjc.2013.108